ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- Pts confirmed GBM, GS, AA, AO & AOA w recurrent disease following standard therapy consisting of at least external beam XRT & temo chemo
- Pts not had tumor biopsy <1 week/surgical resection <2 weeks prior to starting study drug
- Pts should be on non-increasing dose of steroids >7 days prior to obtaining baseline Gd-MRI of brain
- Age >18yrs
- KPS >70
- ANC >1.5 x 10 9/L
- Hgb >9 g/dL
- Platelets >100 x 10 9/L
- AST/SGOT & ALT/SGPT <2.5 x ULN
- Serum bilirubin <1.5 x ULN
- Serum CA <12 mg/dL
- Serum creatinine <1.5 x ULN/measured 24-hr CrCl>50mL/min/1.73m^2
- Pt has ability to understand & provide signed informed consent that fulfills IRB guidelines
- Prior gr3/>toxicity/failure to CPT-11 therapy
- Prior Sunitinib malate therapy
- Concurrent administration of EIAEDs
- Major surgery <2 weeks of enrollment
- History of impaired cardiac function
- Other clinically significant cardiac diseases
- Uncontrolled diabetes
- Active/uncontrolled infection requiring intravenous antibiotics
- Impairment of GI function/GI disease that may significantly alter absorption of
Sunitinib malate Sutent
- Acute/chronic liver/renal disease
- Cerebrovascular accident/transient ischemic attack <6mths of study enrollment
- Pulmonary embolism <6mths of study enrollment
- Pre-existing thyroid abnormality w thyroid function that can not be maintained in
normal range w medication
- Pts taking warfarin sodium
- Pts have received chemo ≤4wks to starting study drug unless they have fully recovered
from all anticipated side effects of such therapy
- Pts have received immunotherapy ≤2wks to starting study drug/have not recovered from
side effects of such therapy
- Pts have received investigational drugs ≤2wks to starting study drug unless they have
fully recovered from all anticipated side effects of such therapy
- Pts have received XRT ≤4wks to starting study drug unless they have fully recovered
from all anticipated side effects of such therapy
- Pts have undergone major non-CNS surgery ≤2wks to starting study drug/pts who have not
recovered from side effects of such therapy
- Cardiac pacemaker
- Ferromagnetic metal implants other than those approved as safe for use in MR scanners
- Claustrophobia
- Obesity
- Female pts who are pregnant/breast feeding/adults of reproductive potential not
employing effective method of birth control
- Known diagnosis of HIV
- History of another primary malignancy that is currently clinically
significant/currently requiring active intervention
- Pts unwilling to/unable to comply w protocol
- Existing intra-tumoral hemorrhage
- Concurrent participation in another clinical trial except for supportive
care/non-treatment trials
- Other severe acute/chronic medical/psychiatric condition/lab abnormality that may
increase risk associated w study participation/study drug administration/ may
interfere w interpretation of study results, & in judgment of investigator would make
subject inappropriate for entry into this study
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Durham, North Carolina
- Durham, North Carolina
- Phoenix, Arizona
- Little Rock, Arkansas
- New Haven, Connecticut
- Orlando, Florida
- Atlanta, Georgia
- Chicago, Illinois
- Evanston, Illinois
- Edgewood, Kentucky
- Edgweood, Kentucky
- Lexington, Kentucky
- Boston, Massachusetts
- Lebanon, New Hampshire
- Edison, New Jersey
- Summit, New Jersey
- Cincinnati, Ohio
- Philadelphia, Pennsylvania
- Pittsburgh, Pennsylvania
- Dallas, Texas
- Charlottesville, Virginia
- St. Leonards, New South Wales
- East Bentleigh, Victoria
- Clayton,
- Graz,
- Wien,
- Calgary, Alberta
- Vancouver, British Columbia
- Winnipeg, Manitoba
- Moncton, New Brunswick
- Halifax, Nova Scotia
- Hamilton, Ontario
- Ottawa, Ontario
- Toronto, Ontario
- Split,
- Zagreb,
- Hradec Kralove,
- Praha 5,
- Lyon,
- Nantes St. Herblain,
- Berlin,
- Mainz,
- Regensburg,
- Tuebingen,
- Bangalore,
- Bologna,
- Padova,
- Moscow,
- Cape Town,
- Pretoria,
- Badalona,
- Hospitalet de Llobregat,
- Oviedo,
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Ph I SU011248 + Irinotecan in Treatment of Pts w MG | |||
| Official Title ICMJE | A Phase I Study of SU011248 Plus Irinotecan in the Treatment of Patients With Malignant Glioma | |||
| Brief Summary | Primary Objectives To determine maxi tolerated dose & dose limiting toxicity of SU011248 + Irinotecan in recurrent MG pts not on EIAEDs To characterize safety & tolerability of SU011248 + Irinotecan among pts w recurrent MG Secondary Objectives To evaluate pharmacokinetic profile of SU011248 & Irinotecan when co-administered in pts w MG To evaluate anti-tumor activity of SU011248 + Irinotecan | |||
| Detailed Description | Primary interest for combining SU011248 w irinotecan in malignant glioma pts derives from dramatic anti-tumor activity recently demonstrated among RMG pts treated w humanized anti-VEGF monoclonal antibody, bevacizumab, when combined w irinotecan. 63 percent radiographic response rate was observed following treatment w regimen every other wk, & median progression-free survival was 23wks. Similar enhancement of chemo activity by VEGF-directed therapy w bev has been previously demonstrated for colorectal & lung cancer pts. SU011248 is being evaluated in current regimen because it may exert more potent anti-angiogenic effect than bev among MG pts due to its ability to inhibit PDGFR-mediated pericyte stabilization in tumor neovasculature. Current proposed ph I study is designed to determine MTD & DLT of SU011248 when combo w irinotecan for pts w RMG. Both SU01148 & irinotecan are known to be metabolized by CYP3A4 cytochrome system. Current study will limit enrollment to pts who are not on CYP3A4-enzyme inducing anti-epileptic drugs. | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 1 | |||
| Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
| Condition ICMJE | Glioblastoma | |||
| Intervention ICMJE | Drug: SU011248 & Irinotecan
Sutent given in daily oral manner for 1st 4 wks of each 6wk cycle. You will not take any Sutent during last 14 days of each 6 wk cycle. CPT-11 will be given intravenously over 1 & 1/2 hrs on 1st day of each cycle & then again on days 14 & 28. Sutent is approved for adult subjects w some forms of kidney cancer. It is considered "investigational" for brain tumors. Dosing will begin on day 1 of cycle 1 & continue daily for 4 wks by mouth. Irinotecan is approved for adult subjects with some forms of colorectal cancer. It is also considered "investigational" for brain tumors. Irinotecan dose will depend on your height & weight. Irinotecan will be given intravenously over 90 min on days 1, 14 & 28 of 6wk cycle. You will be seen in clinic approximately every 42 days for 1st 3 cycles of study drug, & then every other cycle thereafter. Your brain MRI examination will be done within 1 wk prior to completion of cycles 1-3, & then within 1 week prior to completion of every other cycle. Other Names:
| |||
| Study Arms ICMJE | Not Provided | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 25 | |||
| Original Estimated Enrollment ICMJE | 30 | |||
| Actual Study Completion Date ICMJE | September 2010 | |||
| Actual Primary Completion Date | June 2010 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | United States | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00611728 | |||
| Other Study ID Numbers ICMJE | Pro00000931 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Duke University | |||
| Study Sponsor ICMJE | Duke University | |||
| Collaborators ICMJE | Pfizer | |||
| Investigators ICMJE |
| |||
| PRS Account | Duke University | |||
| Verification Date | December 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||